Detalhe da pesquisa
1.
Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study.
Int J Clin Oncol
; 28(7): 872-879, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37171692
2.
Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Int J Clin Oncol
; 24(12): 1543-1548, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-31352631
3.
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
Anticancer Drugs
; 28(5): 565-567, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28225456
4.
Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma.
Intern Med
; 62(18): 2731-2735, 2023 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36642523
5.
Pulmonary manifestation of inflammatory bowel disease: Two case reports.
Respir Med Case Rep
; 45: 101914, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37719886
6.
Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer.
Thorac Cancer
; 13(15): 2142-2151, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35719112
7.
A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.
Anticancer Res
; 42(2): 709-722, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-35093869
8.
Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report.
Onco Targets Ther
; 15: 637-642, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35698605
9.
Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma.
Mol Clin Oncol
; 16(4): 87, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35251638
10.
Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Thorac Cancer
; 12(11): 1690-1698, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33939301
11.
Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2.
Thorac Cancer
; 12(6): 906-913, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33528892
12.
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Thorac Cancer
; 11(4): 1052-1060, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32096610
13.
Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Intern Med
; 58(10): 1479-1484, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31092773
14.
Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
Lung Cancer
; 131: 69-77, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31027701
15.
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab.
Onco Targets Ther
; 11: 5879-5883, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30271171
16.
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis.
Oxf Med Case Reports
; 2018(11): omy094, 2018 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-30364514
17.
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression.
Onco Targets Ther
; 11: 5601-5605, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30237726